On March 6, 2024 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, reported that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences (Press release, Sensei Biotherapeutics, MAR 6, 2024, View Source [SID1234640867]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s presentations are as follows:
Keystone Symposia’s Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance
Title: VISTA checkpoint targeting by SNS-101, a pH-selective antibody with enhanced safety and pharmacokinetic profiles, alters the tumor microenvironment and overcomes immune checkpoint inhibitor resistance
Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer
Session: Progress in Drugging the TIGIT and VISTA Pathways
Date and time: Tuesday, March 19, 2024, 3 – 4:30 p.m. PT
Material from the presentation will also be presented in a poster at the conference, as detailed:
Poster Number: 3021
Session: Poster Session 3
Date and time: Wednesday, March 20, 2024, at 7:30 p.m. PT
American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024
Title: Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy
Presentation Type: Poster Presentation
Session Category: Immunology
Session Title: Immune Modulation Employing Agonist or Co-Stimulatory Approaches
Date and Time: Tuesday, April 9, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 3
Abstract Number: 5294